Table 4.

Clinical trials with third party epstein barr virus cytotoxic T lymphocytes

Study	Patient number	Type of transplant or cancer targeted	(CTL line	GVHD	Results
Haque et al. (102)	8	SOT	Closely matched allogeneic EBV specific T cells	None	3 attained CR; 2 did not respond, 3 did not complete treatment
Haque et al. (86)	33	SOT and HSCT	Closely matched allogeneic EBV specific T cells	None	14 attained CR, 3 had a PR and 16 had no response at 6 months
Gandhi et al. (103)	3	SOT	Closely matched allogeneic EBV specific T cells	None	2 attained CRs,
Sun et al. (90)	2	SOT	Closely matched allogeneic EBV specific T cells	None	2 attained CRs (one also received radiotherapy)
Barker et al. (104) Doubrivina et al. (2)	5	HSCT including cord	Closely matched allogeneic EBV specific T cells	None	4 attained CR: 1 had progressive disease
Uhlin et al. (42)	1	Cord	Haploidentical GLC-peptide separated T cells	None	1 attained CR Recurrence 9 months later responded to 2nd infusion
Leen et al. (87)	9	HSCT	Closely matched allogeneic trivirus specific T cells	1	6 attained CR or PR: 2 had no response
Comoli et al. (88)	1	Nasopharyngeal cancer	Matched sibling EBV-specific T cells	None	Disease stabilization
Sun et al. (90)	4	EBV lymphoma	Matched sibling (2) or closely matched (2) EBV-specific T cells	None	1 CR, 1CR but with radiation as well, 1PR
Lucas et al.	6	EBV Positive Hodgkin lymphoma	Closely matched allogeneic EBV specific T cells	None	5 patients with measurable responses

Abbreviations: SOT, solid organ transplant; PTLD, post transplant lymphoproliferative disease; CR, complete remission; PR, partial remission